Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.52 USD

0.52
662,649

+0.01 (2.94%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.52 0.00 (0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SGMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Sangamo Therapeutics, Inc. [SGMO]

Reports for Purchase

Showing records 281 - 300 ( 321 total )

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 281

02/06/2013

Company Report

Pages: 9

Q4 Financials Reaffirm Extended Cash Runway; Next: Transforming HIV Program Clinical Catalysts In H1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 282

12/13/2012

Company Report

Pages: 8

Disruptive In Vivo Protein Replacement Platform Could Reduce ERT Costs For Monogenic Diseases

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 283

10/24/2012

Company Report

Pages: 7

Q3 Financials Were Uneventful; Cash Runway Covers Multiple Catalysts; Reiterate OUTPERFORM And $9 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 284

10/17/2012

Daily Note

Pages: 5

Preclinical Data Presented At Society for Neuroscience Provides Novel Mechanism For Treating Huntington''s Disease;

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 285

08/15/2012

Industry Report

Pages: 24

Life Sciences MAC Best Ideas Conference - New York City - August 14 & 15, 2012 Day 1 Key Takeaways

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 286

07/25/2012

Company Report

Pages: 7

Q2 Financials Were Uneventful; Cash Runway Covers Multiple Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 287

07/20/2012

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 288

05/03/2012

Company Report

Pages: 7

Q1 Financials Were Uneventful and There Is Plenty of Cash to Cover Multiple Transforming Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 289

04/02/2012

Daily Note

Pages: 5

Publication of Preclinical Data Highlights Advantages of ZFN-Based Approach to Cancer Immunotherapy. Reiterate OUTPERFORM and $9 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 290

03/08/2012

Daily Note

Pages: 5

CROI Clinical Data Continue To Suggest Positive

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 291

02/09/2012

Company Report

Pages: 7

2011 Financials Were Uneventful: We See Significant Progress on the HIV Program in 2012 With Cash Runway for Several Years. Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 292

02/03/2012

Industry Report

Pages: 5

Semiconductor Industry Association (SIA) December Data: Revenue Increases M/M

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 293

02/01/2012

Daily Note

Pages: 5

Corporate Update: First Therapeutic Partnership Announced. Reiterate OUTPERFORM and $9 Fair Value.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 294

01/22/2012

Industry Report

Pages: 25

Ue with Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 295

01/13/2012

Daily Note

Pages: 5

2012 Could Be Transformational With HIV Phase 2 Data and the First Therapeutic Partnership.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 296

12/13/2011

Daily Note

Pages: 5

Preclinical Data Presented at ASH Shows Potential for ZFP Approach to Treating Hemophilia and Leukemia. Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 297

10/25/2011

Company Report

Pages: 6

Q3 Financials: We See Significant Progress on the HIV Program in 2012 with Cash Runway Well Into 2013. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 298

10/10/2011

Industry Report

Pages: 21

Q4 2011 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 299

10/03/2011

Company Report

Pages: 6

Reducing FV to $9 from $13 Following Discontinuation of SB-509. Despite Today''s Weakness

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 300

09/19/2011

Company Report

Pages: 5

Data Showing Restoration of T-Cells and Potential Antiviral Activity with SB-728-T

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party